{"id":273281,"date":"2025-10-03T01:14:16","date_gmt":"2025-10-03T01:14:16","guid":{"rendered":"https:\/\/www.europesays.com\/us\/273281\/"},"modified":"2025-10-03T01:14:16","modified_gmt":"2025-10-03T01:14:16","slug":"pfizer-agrees-to-lower-prescription-drug-costs-for-medicaid-in-a-deal-with-trump","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/273281\/","title":{"rendered":"Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump"},"content":{"rendered":"

WASHINGTON<\/strong> \u2013 Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.<\/p>\n

Trump made the announcement at the White House alongside Pfizer CEO Albert Bourla just hours ahead of a possible government shutdown<\/a> in a partisan standoff over health care and spending.<\/p>\n

Pfizer Inc.<\/a>, one of the largest U.S. drugmakers, produces the COVID-19 vaccine Comirnaty and the treatment Paxlovid<\/a>. Its products also include several cancer drugs, the blood thinner Eliquis and Prevnar pneumonia vaccines.<\/p>\n

Under the deal, New York-based Pfizer will charge most-favored-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations.<\/p>\n

Pfizer also agreed to participate in a new website the administration plans to start called TrumpRx, which will allow people to buy drugs directly from manufacturers. Pfizer said many of its treatments will be offered at discounts that average 50% through that platform. <\/p>\n

The agreement builds on an executive order<\/a> Trump signed in May, setting a deadline for drugmakers to electively lower prices or face new limits on what the government will pay. Trump said deals with other drug companies would be coming over the next week.<\/p>\n

\u201cI can\u2019t tell you how big this is,\u201d the president said Tuesday.<\/p>\n

\u201cWe are turning the tide and we are reversing an unfair situation,\u201d Bourla said.<\/p>\n

But prescription drug pricing expert Stacie Dusetzina said it isn’t clear yet the extent of the pricing changes that will occur. The Vanderbilt University Medical Center professor noted that Pfizer is keeping specific terms of the deal confidential, and it wasn’t clear how different any new pricing levels will be from what Medicaid already pays Pfizer.<\/p>\n

Consumers are not expected to start seeing lower prices under the Pfizer deal until 2026, according to senior administration officials who were not authorized to speak publicly and spoke on condition of anonymity.<\/p>\n

Patients in Medicaid, the state and federally funded program for people with low incomes, already pay a nominal co-payment of a few dollars to fill their prescriptions, but lower prices could help state budgets that fund the programs.<\/p>\n

Lower drug prices also will help patients who have no insurance coverage and little leverage to negotiate better deals on what they pay. But even steep discounts of 50% found through the administration’s website could still leave patients paying hundreds of dollars a month for some prescriptions.<\/p>\n

Drugmakers in the past couple of years have started launching websites to connect customers directly with some products,<\/a> such as obesity treatments or the blood thinner Eliquis<\/a>.<\/p>\n

But Dusetzina said selling drugs like that directly to consumers will help only a small number of people.<\/p>\n

\u201cTheoretically there are some who will benefit, but in general this is not a solution for lowering drug prices,\u201d she said.<\/p>\n

Besides committing to lowering costs, Trump said, Pfizer agreed to spend $70 billion in domestic manufacturing facilities, becoming the latest in a string of major drugmakers to announce plans to build production in the United States.<\/p>\n

The White House did not immediately release details about the investment, but Pfizer said in a statement that the outlay would be dedicated to U.S. research, development and capital projects in the next few years.<\/p>\n

Trump has been talking for months about the need to lower drug prices and to boost U.S. drug manufacturing. To persuade companies to strike deals, Trump said he threatened to impose tariffs<\/a> \u2014 a favorite tool of his to use as leverage across all areas of government \u2014 but that move could raise drug prices.<\/p>\n

Trump said the tariff threat put the government in \u201ca pretty good negotiating position,\u201d and said, \u201cThis is something that most people said was not doable.\u201d<\/p>\n

One thing that is not doable, however, was Trump\u2019s repeated claim that it would cut drug prices by more than 100%<\/a>, \u201c14, 15, 1,600% reductions in some cases,\u201d he said.<\/p>\n

A 100% reduction would make the drugs free. Cuts greater than that would essentially mean people are paid to take the drugs. <\/p>\n

Trump sent letters in late July to executives at 17 pharmaceutical companies about changes he would like to see. Copies of the letters posted on social media note that U.S. prices for brand-name drugs can be up to three times higher than averages elsewhere.<\/p>\n

The letters called for drugmakers to commit by Monday to offering what Pfizer agreed to: most-favored-nation pricing to Medicaid and new medications. <\/p>\n

Trump also asked drugmakers to offer the lower pricing levels for drugs sold directly to consumers and businesses.<\/p>\n

Trump has claimed<\/a> that the U.S., with its higher drug prices, subsidizes care in other countries.<\/p>\n

Drug prices for patients in the U.S. can depend on a number of factors, including the competition a treatment faces and insurance coverage. Most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare, which shield them from much of the cost.<\/p>\n

While Trump was focusing on drug costs on Tuesday, Democrats were focused on reversing Medicaid cuts in the sweeping law<\/a> he signed this summer. <\/p>\n

They were pushing for that reversal to be included in a measure to fund the government in the short term, along with an extension of tax cuts that make health insurance premiums more affordable for people who purchase coverage through Affordable Care Act marketplaces. <\/p>\n

Republicans have said they won’t negotiate.<\/p>\n

___<\/p>\n

Murphy reported from Indianapolis.<\/p>\n

Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.<\/p>\n","protected":false},"excerpt":{"rendered":"WASHINGTON \u2013 Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck…\n","protected":false},"author":3,"featured_media":273282,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[141624,64,7824,69,210,1060,15010,67,132,68,93],"class_list":{"0":"post-273281","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-albert-bourla","9":"tag-business","10":"tag-coronavirus","11":"tag-donald-trump","12":"tag-health","13":"tag-medication","14":"tag-robert-f-kennedy-jr","15":"tag-united-states","16":"tag-unitedstates","17":"tag-us","18":"tag-washington-news"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115307588138441685","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/273281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=273281"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/273281\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/273282"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=273281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=273281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=273281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}